SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending amidst discussions about defense contracts, particularly the "Golden Dome" project, potentially driving significant growth. Community members are speculating on contract news and the company's laser technology applications in defense, suggesting a possible breakout. Some traders are expressing bullish sentiments, anticipating a short squeeze and setting high sell targets, while others note the stock's high valuation and potential for manipulation.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Despite strong earnings and AI prospects, Broadcom ($AVGO) is trending down as investors express concerns about margin compression and customer concentration. The community is debating whether this dip represents a buying opportunity or the start of a larger correction in the AI sector. Discussions also focus on potential recovery catalysts and the stock's oversold condition.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to social media hype around its low float and potential for a short squeeze, with many traders eyeing key breakout levels. Community members are actively discussing price targets and comparing ARBB's setup to other recent low-float runners. The stock's recent AI server deal and blockchain developments may also be contributing to the increased attention.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as traders weigh biotech's potential amid broader market uncertainty and upcoming economic data. Community discussions focus on identifying entry and exit points, with some highlighting technical indicators suggesting a possible shift in momentum. Bullish sentiment remains, fueled by potential rate cuts and sector rotation.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar Corp ($SATS) is trending due to speculation surrounding its SpaceX holdings and potential benefits from a SpaceX IPO, with community members weighing the value of its SpaceX stake against the company's debt. Recent news of a spectrum sale to SpaceX and subsequent FCC review adjustments are also fueling the discussion, alongside Morgan Stanley's upgrade and price target increase.  Additionally, Firefly's acquisition of SciTec has sparked conversation about space sector acquisitions and potential bullish moves.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending as traders discuss potential resistance for XBI around the 111 area, anticipating a possible pullback. Community members are debating entry points and whether current market conditions warrant adding to or reducing positions in this leveraged inverse ETF. Ongoing concerns around potential government shutdowns and trade war escalations are also influencing sentiment.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum ($LITE) is trending due to positive sentiment around its role in AI infrastructure, particularly after strong earnings reports and revenue guidance. Community discussions highlight its potential for growth and undervaluing compared to peers, with some suggesting it's a takeover target. Some are drawing comparisons to names like Nvidia ($NVDA) during their early expansion.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the community discusses its AI & Autonomy Day and the unveiling of its new in-house AI chip, sparking debates about its potential to rival Tesla in the autonomous vehicle space. Bullish sentiment is fueled by Needham's price target increase, while some express concerns regarding cash burn and the timeline for R2 vehicle production. The community is closely watching for a potential short squeeze.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as SpaceX IPO buzz fuels broader interest in space stocks, despite a recent scrubbed launch. Community members are speculating on potential catalysts like government contracts and Neutron's progress, with some eyeing ambitious price targets while touting RKLB's reliability in the small launch sector.

Constellation Brands, Inc. engages in the production, marketing, and distribution of beer, wine, and spirits. It operates through the following segments: Beer, Wine and Spirits, Corporate Operations and Other, and Canopy. The Beer segment includes imported and craft beer brands. The Wine and Spirits segment sells wine brands across all categories-table wine, sparkling wine, and dessert wine-and across all price points. The Corporate Operations and Other segment refers to the costs of executive management, corporate development, corporate finance, human resources, internal audit, investor relations, legal, public relations, and information technology. The Canopy segment consists of canopy equity method Investments. The company was founded by Marvin Sands in 1945 and is headquartered in Rochester, NY.

Constellation Brands Inc - Ordinary Shares - Class A

Constellation Brands Inc

Constellation Brands ($STZ) is trending due to a mix of factors including recent downgrades and concerns about weaker consumer demand, especially among its core Hispanic demographic. Despite some analysts highlighting its strong brands and potential for a turnaround, community sentiment appears mixed, with some expressing frustration over recent performance while others see it as a long-term value play, potentially oversold. Discussions also involve the stock's relationship with cannabis companies and potential impacts from broader economic trends and government policies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dogwood Therapeutics, Inc. (DWTX) shares surged 50% in the pre-market session on Monday after the company announced that it has secured a license to develop Serpin Pharma’s intravenous formulation of SP16 to manage cancer-related pain (CRP).The royalty-free, global license will enable the company to develop SP16 for a broad range of chemotherapy-induced neuropathy symptoms as well.In return, Sepin Pharma and its designated affiliates will get 7.31% of the company’s common stock, on a fully diluted basis. This includes 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, it said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Dogwood <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157595/0/en/Dogwood-Therapeutics-Secures-Exclusive-Worldwide-Royalty-Free-License-to-Develop-and-Commercialize-SP16-as-a-Treatment-for-Cancer-Related-Pain-in-an-All-Stock-Transaction-Underscor.html">said</a> that SP16 has demonstrated both anti-inflammatory and neural repair activity. An early-stage trial of the intravenous formulation of SP16, fully funded by the National Cancer Institute, is slated to start patient enrollment in the first half of 2026.“The National Cancer Institute’s funding of the SP16 IV Phase 1b program obviates the need to use our existing capital in the near-term to advance SP16 into clinical development,” CEO Greg Duncan said.The company also noted that SP16 could complement its lead candidate Halneuron, which has demonstrated statistically significant and clinically meaningful pain reductions in general cancer pain, as well as chemotherapy-induced neuropathic pain, respectively.DWTX stock has more than tripled this year and risen by about 79% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug 

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.

Equity

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.


Shares of Dogwood Therapeutics Inc. rose over 18% in premarket trading Friday, following a jaw-dropping 370% surge in the previous session.&nbsp;Trading volume was over 62 times the daily average, with retail investors on Stocktwits making it the most discussed biotech stock before the bell.While there was no fresh news on Friday, the rally appears to stem from an&nbsp;earlier announcement.&nbsp;Dogwood disclosed on Tuesday that it plans to begin dosing the first patient in its Phase 2b HALT-CINP trial in the first quarter of 2025.&nbsp;The trial evaluates Halneuron, a non-opioid therapy aimed at alleviating neuropathic pain linked to chemotherapy.The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.&nbsp;Retail attention on Stocktwits has skyrocketed. The stock saw an 8,500% jump in message volume on Thursday, with&nbsp;its retail&nbsp;following increasing by 18% in a single day.&nbsp;<stembedurl>https://stocktwits.com/OFFC18/message/601301523</stembedurl><stembedurl>https://stocktwits.com/BullsEye2000/message/601306713</stembedurl>Dogwood stock is up over 400% year-to-date and has lost 95% over the past 12 months.&nbsp;The massive surge has reignited attention, although its low liquidity and early-stage pipeline make it a volatile bet.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge

The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Current Price	$6.82
Prev Close	$6.42
Open	$6.42
Dividend Yield	0.00%
50-Day Moving Average	$6.03
Beta	0.69
Avg. Volume	31,921.42
PE Ratio	-0.27

52-Week High	$29.28
52-Week Low	$1.87
Market Capitalization	$202.8M
EPS (Annual)	-$12.52
Price to Book	-0.47
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

DWTX
Dogwood Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DWTX News

DWTXDogwood Therapeutics Inc.